CLINICAL USE

Urinary frequency, urgency and incontinenceNeurogenic bladder instability and nocturnal enuresis

DOSE IN NORMAL RENAL FUNCTION

2.5–5 mg 2 to 3 times a day; maximum 5 mg 4 times a dayXL: 5–20 mg once daily Patches: 1 patch (36 mg) twice weekly

PHARMACOKINETICS

  • Molecular weight                           :393.9
  • %Protein binding                           :83–85
  • %Excreted unchanged in urine     : <0.1
  • Volume of distribution (L/kg)       :193 litres
  • half-life – normal/ESRD (hrs)      :1.1–3 (XL: 12–13) /–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Dialysed. Dose as in normal renal function
  • HD                     :Dialysed. Dose as in normal renal function
  • HDF/high flux   :Dialysed. Dose as in normal renal function
  • CAV/VVHD      :Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsOther antimuscarinic agents: increased antimuscarinic effects

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral, topical

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Start with a low dose in elderly patients and those with renal impairment, and increase according to response

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia